ABVV Abviva Inc

[mickymoose99]

Abviva Announces Further Patent Issuance for Technology Used in Breast Cancer Diagnostics and Therapeutics

Buzz up! 0 Print..Companies:ABVIVA INC.Related Quotes
Symbol Price Change
ABVV.PK 0.05 0.00


{"s" : "abvv.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00", "o" : "","j" : ""} Press Release Source: Abviva, Inc. On Monday May 17, 2010, 4:15 pm EDT
SANTA BARBARA, Calif., May 17 /PRNewswire-FirstCall/ -- Abviva, Inc. (Pink Sheets:ABVV.pk - News), a biomedical company engaged in the development and commercialization of breast cancer related applications of Mammastatin, announced today that the Japanese Patent Office issued two patents on the core technology that may be used for therapeutic applications and in the Company's breast cancer risk assessment test, the Mammastatin Serum Assay (MSA). The patents are the most recent of 13 international and U.S. patents to issue to the University of Michigan for breast cancer diagnostic and therapeutic uses of Mammastatin.

"We are very pleased with this positive development," said Barrett Evans, CEO of Abviva. "Not only will these patent grants allow us to penetrate the Japanese market with proprietary technology, they further validate, along with previous patent grants covering 16 European countries, Canada, Australia, and the United States, the global patentability of the Mammastatin technology."

The MSA was initially developed at the University of Michigan Cancer Center and is licensed exclusively to Abviva by the University for scientific and commercial development as a blood test to assess women's health. In scientific correlation studies women who tested high with the MSA test showed to have lower risk of breast cancer than women who tested low. These findings align with results of the original research conducted at the University of Michigan Cancer Center that demonstrated Mammastatin was normally produced by breast epithelial cells in healthy women and was missing or reduced in transformed breast epithelial cells.

"This further solidifies the domestic and international intellectual property protection strategy we have implemented with the University of Michigan," continued Mr. Evans. "The issuance of this patent will be very important as we gain regulatory approval and market presence for the Mammastatin technology internationally. These newest patent grant notifications further expand our worldwide patent protection and marketability for MSA."

About Abviva

Abviva, Inc. is a biomedical company engaged in the innovation, development and commercialization of breast cancer related applications of Mammastatin, a growth inhibitory protein discovered at the University of Michigan Cancer Center that demonstrated anti-breast cancer properties. The discovery was developed into a simple breast cancer diagnostic blood test that demonstrated healthy women have high or normal levels of the protein and women with breast cancer have no detectable or very low levels of the protein. Abviva intends to commercialize the Mammastatin Serum Assay as a reference test through its wholly owned subsidiary laboratory under CLIA certification.

[STOCKMAN]

Heres another pr from ABVV. This one exploded on the last news release. I think were are going to have another great run with some high volume and some nice gains again this week. Imo we are going to ahve a huge morning. Keep your eyes on this one!! Here is the news..

SANTA BARBARA, Calif., May 21 /PRNewswire-FirstCall/ -- Abviva, Inc. (Pink Sheets:ABVV.pk - News), a biomedical company engaged in the development and commercialization of breast cancer related applications of Mammastatin, today provided further details about worldwide patent protection for its breast cancer risk assessment technology.

The Company previously announced that the Japanese Patent Office issued two patents on the core technology that may be used for therapeutic applications and in the Company's breast cancer risk assessment test, the Mammastatin Serum Assay (MSA). The patents are the most recent of 13 international and U.S. patents to issue to the University of Michigan for breast cancer diagnostic and therapeutic uses of Mammastatin.

The international patents detail methods of use and compositions of Mammastatin in therapeutic and diagnostic applications in the United States (7 patents), Australia (2 patents), Canada (1), Europe (1), and Japan (2). These patents have issued starting in the United States and Australia in 2002, and continuing through the two most recent patents issued this year in Japan.

"Based upon the patents, we believe that we will be able to aggressively penetrate the largest markets worldwide with confidence that our intellectual property is secure," said Barrett Evans, CEO of Abviva. "There are additional patents that have been filed and we are hopeful that we will be able to obtain even further protection of our intellectual property as the Company grows."

The MSA was initially developed at the University of Michigan Cancer Center and is licensed exclusively to Abviva by the University for scientific and commercial development as a blood test to assess women's health. In scientific correlation studies women who tested high with the MSA test showed to have lower risk of breast cancer than women who tested low. These findings align with results of the original research conducted at the University of Michigan Cancer Center that demonstrated Mammastatin was normally produced by breast epithelial cells in healthy women and was missing or reduced in transformed breast epithelial cells. In previous studies, an independent biostatistician calculated the overall accuracy of the MSA test to be 84-86%.

"This further solidifies the domestic and international intellectual property protection strategy we have implemented with the University of Michigan," continued Mr. Evans. "The issuance of this patent will be very important as we gain regulatory approval and market presence for the Mammastatin technology internationally. These newest patent grant notifications further expand our worldwide patent protection and marketability for MSA."

[STOCKMAN]

Keep your eyes on ABVv this morning. This one isnt showing any life today but Imo this will have a late start. They stated in there last news statement that they have more patents in the works and there are rumors everywhere about news coming on this one.

Breast cancer is becoming very common in women and they have seen some cases starting to show in men. Reaserch shows that Mammastatin is deficient in women with breast cancer. Abviva has made a serum and is used on women with early breast detection and has amazing results. It has also been used on women with terminal breast cancer. The results from this have shown regression of bone metastatic tumorsand has extended there lives two years or more.

Imo this is a great company to take a position in. I belive they are on the right track in the battle with breast cancer. This company is definatly undervalued and in time will become a major player for the fight against breast cancer. The company is constanly looking for bigger and better ideas and there reasearch is what will make breast cancer a thing of the past!